Know What's Happening in Biohacking

[Comment] Hypofractionated Nodal Radiotherapy in Breast Cancer: Time for an Updated Standard of Care?

The Lancet comment revisits hypofractionated nodal radiotherapy for breast cancer, highlighting its historical association with lymphoedema and brachial plexopathy due to high doses and poor protocol control. Early adoption of hypofractionation was driven by capacity constraints rather than trial evidence, fostering clinician scepticism. Recent data from the FAST‑Forward nodal sub‑study and other phase‑III trials demonstrate non‑inferior toxicity and comparable oncologic outcomes with five‑fraction schedules. The authors argue that these findings merit an update to standard‑of‑care guidelines.